New combo therapy targets Tough-to-Treat myeloma

NCT ID NCT06550895

Ongoing Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Sep 30, 2025 · Last updated May 14, 2026 · Updated 26 times

Summary

This study tests a combination of two treatments—cilta-cel (a cell therapy) and talquetamab (a targeted drug)—in people with high-risk multiple myeloma that has not responded well to prior therapies. The main goal is to check safety, and researchers will also measure how many patients see their cancer shrink or disappear. The study is small (11 participants) and is currently active but not recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Austin Hospital

Heidelberg, 3084, Australia
Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Norton Cancer Institute

Louisville, Kentucky, 40207, United States
Peter MacCallum Cancer Centre

Melbourne, 3000, Australia
Royal Prince Alfred Hospital

Camperdown, 2050, Australia
The Alfred Hospital

Melbourne, 3004, Australia
University of Iowa Hospital and Clinics

Iowa City, Iowa, 52242, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Conditions

Explore the condition pages connected to this study.

MULTIPLE MYELOMA